Our Team   |   Publications |  Presentations   |   Contact Us                                             Home

1. Janosik JE, Bettmann MA, Kaul AF, Souney PF. Therapeutic alternatives for subacute peripheral arterial occlusion: Comparison by outcome, length of stay, and hospital charges. Invest Radiol 1991; 26:921-5.

2. Kaul AF. Medical outcomes management and cost-benefit considerations: An overview. Invest Radiol 1994; 29 (Supplement 1):S59-S63.

3. Kaul AF. Pharmacoeconomic Considerations in Peripheral Arterial Thrombolytic Therapy. JVIR 1995; 6:104S-110S. (Abstract)

4. Aforismo JF, Kaul AF, Tomondy PA, Parry GE, Staubach LB, Regalli G, Dine AP. Floroquinolone use for acute cystitis in an IPA-model managed care organization. Am J Health Syst Pharm 1995;52:2702-4.

5. Kaul AF, Tomera JF. DUE criteria for use of regional urokinase infusion for deep vein thrombosis. Am J Health System Pharm 1997;54:2002-3.

6. Kaul AF, Tomera JF. DUE criteria for use of regional urokinase infusion for peripheral arterial occlusion. Am J Health System Pharm 1997:54:2000-1.

7. Tomera JF, Kaul AF, Regional thrombolytic infusion for peripheral arterial occlusion and deep vein thrombosis: Tried and true. Am J Health System Pharm 1997;54:1988-91.

8. Bramlet DA, King HM, Witt JR, Bosch RJ, Kaul AF. Cholesterol management by interventional and invasive cardiologists: Results from a QA audit in patients with coronary heart disease. Am J Cardiol 1997: 80(7a):675.

9. Bramlet DA, King HM, Young L, Witt JR, Stoukides CA, Kaul AF. Management of hypercholesterolemia: Practice patterns for primary care providers and cardiologists. Am J Cardiol 1997;80(8B):39H-44H.(Abstract)

10. Bramlet DA, Stoukides CA, Kaul AF, Hsiao LD. A comparison of hypercholesterolemia management in the secondary prevention of coronary heart disease by payor types: Fee for service, medicare, and managed care organizatios. J Managed Care Pharm 1998;4:483-87.

11. Kaul AF, Stoukides CA, Hsiao LD. Atorvastatin, another HMG CoA reductase inhibitor? Published exclusively on the world wide web at http://medscape.com specialty cardiology practice section.

12.  Stoukides CA, McVoy H, Kaul AF. Candesartan cilexetil review: An angiotensin II receptor blocker. Ann of Pharmacotherapy 1999;33:1287-1298. (Abstract)

13.  Amidon PB, Jankovich R, Stoukides CA, Kaul AF. Proton pump inhibitor therapy: Preliminary results of a therapeutic interchange program. Am J Managed Care 2000;6: 593-601(Abstract)

14.  Hillert B, Remonte S, Rodgers G, Yancy CW, Kaul AF. Improving patient outcomes by pooling resources (The Texas Heart Care Partnership experience). Am. J. Cardiol 2000;85:43A-51A.

15.  LaBresh KA, Owen P, Alteri C, Reilly S, Shea-Albright P, Hordes AR, Shaftel PA, Noonan CA, Stoukides CA, Kaul AF. Seconday prevention in a cardiology group practice and hospital setting after a Heart-Care initiative. Am. J. Cardiol 2000;85:23A-29A.

16.  Kaul AF. Pain Management. In Comprehensive Pharmacy Review, 4th Edition. Shargel L, Mutnick A, Souney PF,   Swanson L (Editors).Baltimore MD. Lipincott Williams & Wilkins, 2000,

17. Castaldo RS, Mato A, Stoukides CA, Kaul AF. Effect of patient education and zanamivir on morbidity of influenza in a private practice. Chest 2000; 4:244S

18. Jan SA, Leach TD, Kaul AF. The formulary management system and decision-making process at Horizon Blue Cross Blue Shield of New Jersey: review of osteoporosis and emerging treatment options. Pharmacotherapy 2001;21:1301

19.Castaldo RS, Mato A, Kaul AF, Gorski H, Bosch RJ, A retrospective analysis of cyclooxygenase-II inhibitor response patterns. J Pharm Technol 2002;18:305-9 (Abstract)

20. Ouriel K, Kaul AF, Leonard MC, Katzen BT. Clinical and economic outcomes in the treatment of peripheral occlusive diseases. Society of Interventional Radiology Annual Meeting. Salt Lake City. March 30,2003

21. Castaldo RS, Cifaldi M, Kaul AF, Castaldo A, Chopko M, Peterson B, Mato A. Treatment of acute exacerbations of chronic bronchitis in patients with chronic obstructive pulmonary disease: A retrospective cohort analysis or Clarithromycin extended release vs. Azithromycin. Chest 2003:124;172S (Abstract)

22. Kenneth Ouriel, MD, Alan F. Kaul, PharmD, MS, MBA, FCCP, and Mandy C. Leonard, BS, PharmD, Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis Journal of Vascular Surgery ;40:971-977 (Abstract)
 

1. Schumock GT, Nair VP, Finley JM, Lewis RK,. Penetration of Medical Safety Technology in Community Hospitals; Journal of Medical Systems, 2003 Dec; 27(6)

2. Nair VP, Rickert, E; Protecting voluntary error reporting systems from disclosure (Pending publication)

3. Nair VP; Generics; Caremark Clinical Update; Caremark Rx Inc.;2002 Sept;1-3

4. Nair VP; Gum Karaya-A wonder drug; KMCH Pharma;1999;1;23-27
 

1. Tuomala RE, Souney PF, Fisher S, Simpson CA, Steele L, Mutnick AH. Double blind comparative study of intravenous cefotaxime or ampicillin in the treatment of postpartum endometritis. Drug Intell Clin Pharm 1987;21:7a.

2. Simpson CA, Souney PF. Calculating costs of drug therapy: A review of a decade of literature (1977-1987). Clin Ther. 1988; 10:615-650.

3. Souney PF, Stoukides CA. Pharmacoeconomic aspects and formulary considerations related to H2-receptor antagonists. Drug Intell Clin Pharm 1989;23:S29-S35.

4. Stoukides CA, Souney PF. Comparison of length of hospital stay and hospital charges in post cesarean section women managed by patient controlled analgesic techniques or intramuscular narcotic analgesics. J Research in Pharmaceutical Economics. 1993;5(2):59-67.
5. Bramlet DA, King HM, Young L, Witt JR, Stoukides CA, Kaul AF. Management of hypercholesterolemia: Practice patterns for primary care providers and cardiologists. Am J Cardiol 1997;80(8B):39H-44H.

6.Gheorghiade M, Benatar D, Konstam MA, Stoukides CA, Bonow RO. Pharmacotherapy for systolic dysfunction: A review of randomized clinical trials. Am J Cardiol 1997:80(8B):14H-27H.

7. Bramlet DA, Stoukides CA, Kaul AF, Hsiao LD. A comparison of hypercholesterolemia management in the secondary prevention of coronary heart disease by payor types: Fee for service, medicare, and managed care organizatios. J Managed Care Pharm 1998;4:483-87.

8. Kaul AF, Stoukides CA, Hsiao LD. Atorvastatin, another HMG CoA reductase inhibitor? Published exclusively on the world wide web at http://medscape.com specialty cardiology practice section.

9. Amidon PB, Jankovich R, Stoukides CA, Kaul AF. Proton pump inhibitor therapy: Preliminary results of a therapeutic interchange program. J Managed Care Pharm 1999;5:410-411 (Abstract)

10.  Stoukides CA, McVoy H, Kaul AF. Candesartan cilexetil review: An angiotensin II receptor blocker. Ann of Pharmacotherapy 1999;33:1287-1298.

11.  LaBresh KA, Owen P, Alteri C, Reilly S, Shea-Albright P, Hordes AR, Shaftel PA, Noonan CA, Stoukides CA, Kaul AF. Seconday prevention in a cardiology group practice and hospital setting after a Heart-Care initiative. Am. J. Cardiol 2000;85:23A-29A.
12.  Amidon PB, Jankovich R, Stoukides CA, Kaul AF. Proton pump inhibitor therapy: Preliminary results of a therapeutic interchange program. Am J Managed Care 2000;6: (accepted for publication)